

11P
Box 500
Patent

Attorney's Docket No. 021565-108

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of)
Christopher A. HELLIWELL) Group Art Unit: Unassigned
Application No.: 10/055,001) Examiner: Unassigned
Filed: January 25, 2002) Confirmation No.: 7679
For: METHODS AND MEANS FOR)
PRODUCING EFFICIENT SILENCING)
... RECOMBINATION CLONING)

TRANSMITTAL LETTER FOR MISSING PARTS OF APPLICATION**BOX: MISSING PART**

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

In complete response to the Office communication concerning the Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence disclosures dated June 5, 2002, enclosed please find:

- [X] A copy of the "Sequence Listing" in computer readable form in compliance with 37 C.F.R. §§1.823(b) and 1.824.
- [X] A statement that the content of the paper and computer readable copies are the same as set forth in 37 C.F.R. §1.821(f).

The Commissioner is hereby authorized to charge any additional fees under 37 C.F.R. §§1.16, 1.17, and 1.21 that may be required by this paper, and to credit any overpayment to Deposit Account No. 02-4800. A duplicate copy of this paper is enclosed.

Respectfully submitted,

BURNS, DOANE, SWECKER & MATHIS, L.L.P.

P.O. Box 1404
Alexandria, Virginia 22313-1404
(703) 836-6620

By: Malcolm K. McGowan
Malcolm K. McGowan, Ph.D.
Registration No. 39,300

Date: 11 June 2002

(05/02)



Patent
Attorney's Docket No. 021565-108

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of)
)
Christopher A. HELLIWELL et al) Group Art Unit: 1632
)
Application No.: 10/055,001) Examiner: Unassigned
)
Filed: January 25, 2002) Confirmation No.: 7679
)
For: METHODS AND MEANS FOR)
PRODUCING EFFICIENT)
SILENCING CONSTRUCT USING)
RECOMBINATION CLONING)

DECLARATION PURSUANT TO
37 C.F.R. §§1.821-1.825

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

I, Malcolm K. McGowan, declare as follows:

1. That the content of the paper and computer readable copies of the Sequence Listing, submitted in accordance with 37 C.F.R. §1.821(c) and (e), respectively, are the same in compliance with §1.821(f).
2. That the submission, filed in accordance with 37 C.F.R. §1.821(g), herein does not include new matter.

I hereby declare that all statements made herein of my own knowledge are true and that all statements were made on information and belief and are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001

of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

11 June 2002
Date

Malcolm K. McGowan
Malcolm K. McGowan, Ph.D.
Registration No. 39,300



UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20230
www.uspto.gov

APPLICATION NUMBER	FILING RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
10 055,001	01/25/2002	Christopher A. Helliwell	021565-108

21839

BURNS DOANE SWECKER & MATHIS L L P
POST OFFICE BOX 1404
ALEXANDRIA VA 22313-1404



CONFIRMATION NO. 7679

FORMALITIES LETTER



OC000000008234968

Date Mailed: 06/05/2002

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d). Applicant must provide a substitute computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

A copy of this notice MUST be returned with the reply.

Customer Service Center
Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE